Health Point Inc. shares are available through ten-to-one warrants in advance of the upcoming initial public offering.

Clinical studies by Health Point Inc. continue to identify crucial stem cell discoveries to produce and stimulate new capillary (angiogenesis) and vessel (vasculogenesis) growth.

Health Point Inc. recently announced another important advance towards the treatment of chronic lower limb ischemia.

Health Point Inc. has now partnered with other lab analysis companies with complementary services to collectively offer client firms a comprehensive spectrum of offerings.

Studies recently published by Health Point Inc. have attracted the attention of several research foundations which have provided access to additional resources and partnerships.

Health Point Inc. shares are available through ten-to-one warrants in advance of the initial public offering scheduled for early 2015.

Health Point Inc. continues to receive rapidly growing interest through early subscriptions from potential investors for its early 2015 initial public offering, pointing to a potential sellout.

Health Point Inc. confirmed that its initial public offering is slated for the first quarter of next year.

Health Point Inc's new, state of the art immunoassay laboratory and production facility has been recognized as being among the most advanced and effective by a consortium of teaching hospitals.

Experimental stem cell techniques developed by Health Point Inc. are showing significant progress in stimulating new vein growth in damaged tissue, a process known as vasculogenesis.

Following the successful completion of phase one, Health Point Inc. announced the commencement of the second phase of expanding research laboratory facilities which are vital to satisfy rapidly increasing demand.

Health Point Inc. announced that it would now offer clients the option of fast track genotyping services when accelerated results are required.

One of the fastest growing services Health Point Inc. provides is immunoassay research and development in support of the development of vaccines for the world's most dangerous viruses.

To further its leadership role in immunoassay research and development, Health Point Inc. his established a research partnerships with several university laboratory facilities.

Health Point Inc. now offers dual matrix genotyping services which provide faster and more accurate genomic DNA extraction for mutation analysis, HLA genotyping, and Fc-gamma Receptor IIIa.

Health Point Inc. is looking to fund capacity building expansions through a highly anticipated IPO later this year.

Health Point Inc's state of the art immunoassay laboratory and production facility has been awarded the highest certification level based on advanced processes and safety standards.

Specializing in immunoassays, Health Point Inc. is pleased to announce that its recently expanded facilities have exceeded all aspects of international clinical safety and accuracy standards.

A series of clinical studies published by senior researchers at by Health Point Inc. has evidenced a direct co-relation between stem cell research to produce and stimulate new capillaries, a process known as angiogenesis.

Health Point Inc. announced this week that the company is the recipient of international recognition for its stem cell research, widely acknowledged to directly contribute to research which will extend human life expectancy

Health Point Inc. now offers extended genotyping services which focuses on genomic DNA or gDNA extraction for mutation analysis.

Health Point Inc. continues to receive strong expressions of interest through pre-sale subscriptions from potential investors for its initial public offering slated for the middle of 2014.

Health Point Inc. has renewed its commitment to deliver safe, effective and affordable stem cell therapies by expanding research and clinical application.

Health Point Inc. recently announced a small but important advance towards treatment of chronic lower limb ischemia.

Health Point Inc. announced the completion of expanded research laboratory facilities that are required to meet rapidly expanding demand.

Health Point Inc. has announced it is receiving strong expressions of interest from potential investors for its initial public offering slated for the middle of 2014.